Healthcare >> CEO Interviews >> April 4, 2011
Scott Cormack is the President and CEO of OncoGenex Pharmaceuticals, Inc. Mr. Cormack has over two decades of diverse experience in the biotechnology industry in executive management and venture capital. He is the Founding President and CEO of the company, and he became the full-time President and CEO in January 2002. Mr. Cormack has led OncoGenex through significant corporate milestones, including serial rounds of private financing, leading the corporation through transition from pre-clinical through completion of multiple Phase II clinical trials and through the development of a robust product candidate pipeline. In December 2009, Mr. Cormack led his team to complete a global collaboration and license agreement with global medicines giant Teva Pharmaceutical Industries Ltd. to support the final stage of development of OGX-011. Mr. Cormack has created a solid foundation for OncoGenex to maximize the broad potential of OGX-011 and a robust pipeline of product candidates, potentially bringing important treatment options to cancer patients. Profile
TWST: Please tell our readers the history and background of Optimer.
Mr. Lichtinger: Optimer (OPTR)is a company that was founded in 1998. It was founded on the basis of a platform that we call OPopS.
